Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Transplacental Administration of Antiarrhythmic Agents Given Conditional Approval
January 18, 2010
- Hatoyama Administration's 1st Budget Proposal for FY2010 Approved by Cabinet
January 18, 2010
- JMA Opposed to Any Decrease in Repeat Consultation Fee Clinics
January 18, 2010
- New Growth Strategy to Focus on Health, Environment, Tourism
January 18, 2010
- 3 Novartis A (H1N1) 2009 Flu Vaccines Prequalified by WHO
January 18, 2010
- DSP Applies for Lurasidone in the US
January 18, 2010
- ON THE MOVE
January 18, 2010
- Teijin Pharma Applies for TMX-67 in Japan
January 18, 2010
- Common Approval System Needed in Asia: Mr Shoda
January 18, 2010
- Herceptin Receives Positive Opinion for Advanced Stomach Cancer from CHMP
January 18, 2010
- Top Management Stresses Need to Develop New Products in New Year's Speeches
January 18, 2010
- Industry Must Make Further Investment in R&D to Introduce Better Pricing System
January 18, 2010
- Reform of Distribution Practices and Drug Pricing System Are Two Sides of the Same Coin: Mr Bessho
January 18, 2010
- Reorganization of Generics Industry to Progress: Mr Sawai
January 18, 2010
- Responses to New Pricing System Most Important Challenge for Wholesalers: Mr Kohno
January 18, 2010
- NJIHK to Start Hansha's MS Certification System
January 18, 2010
- Eisai Completes Acquisition of AkaRx
January 18, 2010
- Japan, China, South Korea to Start Joint Studies on Ethnic Differences
January 18, 2010
- Kyowa Kirin Licenses Bardoxolone from Reata
January 18, 2010
- BI Conducts PIII Trials for 2 Anticancer Agents
January 18, 2010
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…